Use access key #2 to skip to page content.
$0.23 0.01 (4.40%)
1/9/2009 3:59 PM

ENTREMED, INC. (ENMD)

CAPS Rating:
*

A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.

View All Commentary (ENMD)

Recs

2

Avatar hlacheen (98.66) Submitted: 12/21/06 9:39 PM : Underperform Start Price: $1.69 ENMD Score: 49.29

Just look at the income statement and cash flow.... this company is a cash-burning disaster, it is NOT worth $120m

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners

Sponsored Links